Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity (NEDA-4) in relapsing-remitting multiple sclerosis

Conclusion:
NEDA-4 has the potential to capture the impact of therapies on both inflammation and neurodegeneration, and deserves further evaluation across different compounds and in long-term studies.

Source: Multiple Sclerosis - September 6, 2016 Category: Neurology Authors: Kappos, L., De Stefano, N., Freedman, M. S., Cree, B. A., Radue, E.-W., Sprenger, T., Sormani, M. P., Smith, T., Häring, D. A., Piani Meier, D., Tomic, D. Tags: Original Research Papers Source Type: research